Author

Yusuf Yilmaz

OpenAlex ID: A5137178587

LBO-001 A phase 2b/3 trial of saroglitazar in primary biliary cholangitis (EPICS III)

2026 · Raj Vuppalanchi, Alejandra Villamil, et al. · Journal of Hepatology · 1

Erratum: Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study

2026 · Zobair M. Younossi, Leyla de Avila, et al. · Hepatology

Erratum: Noninvasive assessment of liver disease severity in NAFLD and T2D

2026 · Grazia Pennisi, Marco Enea, et al. · Hepatology

FRI-511-YI Sex-based inequities in liver transplant access associated with jaffe creatinine measurement bias: an analysis from the scientific registry of transplant recipients data

2026 · Eda Kaya, Christin Quast, et al. · Journal of Hepatology

THU-015 Gender differences in stigma and care avoidance among people living with metabolic dysfunction–associated steatotic liver disease (MASLD): an international survey

2026 · Patrizia Carrieri, Shira Zelber-Sagi, et al. · Journal of Hepatology

SAT-046 Ultra-processed food intake is associated with obesity and advanced fibrosis in metabolic dysfunction associated steatotic liver disease: a multinational analysis from the global NASH/MASH registry™

2026 · Zobair M. Younossi, Shira Zelber-Sagi, et al. · Journal of Hepatology

FRI-095 Clinician and patient perspectives on stigma, knowledge, and care gaps in alcohol-related liver disease (ALD)

2026 · Zobair M. Younossi, Phunchai Charatcharoenwitthaya, et al. · Journal of Hepatology

SAT-618 Global gaps in hepatitis B (HBV) and D (HDV) care: results from a worldwide survey of clinical practice

2026 · George Papatheodoridis, Maria Buti, et al. · Journal of Hepatology

OS-097 Liver fibrosis is the only predictor of adverse outcomes: time to remove metabolic dysfunction associated steatohepatitis (MASH) resolution as a clinical trial endpoint

2026 · Zobair M. Younossi, Ming-Lung Yu, et al. · Journal of Hepatology

TOP-113 Clinical profile, histologic features, non-invasive test accuracy, and long-term outcomes of lean metabolic dysfunction associated steatotic liver disease (MASLD): insights from the global masld project

2026 · Zobair M. Younossi, Leyla de Avila, et al. · Journal of Hepatology

SAT-254 Seladelpar effect on lipids and muscle safety with concomitant statin use in patients with primary biliary cholangitis: interim results from the open-label ASSURE study with up to 4 years of treatment

2026 · Christopher L. Bowlus, Yusuf Yilmaz, et al. · Journal of Hepatology

TOP-376 Hepatocellular carcinoma (HCC) in patients with biopsy proven metabolic dysfunction associated steatotic liver disease (MASLD)

2026 · Zobair M. Younossi, Daniel Huang, et al. · Journal of Hepatology

SAT-272-YI Spleen stiffness predicts clinical event-free survival in primary biliary cholangitis: a prospective cohort study

2026 · Ilkay Ergenc, Hasan Basri Yapıcı, et al. · Journal of Hepatology

Works count: 13

Citation count: 1

H-index: 1

I10-index: